| Assessment Status | Rapid Review complete |
| HTA ID | 21024 |
| Drug | Cannabidiol |
| Brand | Epidyolex® |
| Indication | As adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older. |
| Assessment Process | |
| Rapid review commissioned | 09/06/2021 |
| Rapid review completed | 08/07/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cannabidiol (Epidyolex®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations December 2021.
